|
1
|
Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress.
|
Proc Natl Acad Sci U S A
|
2005
|
3.08
|
|
2
|
The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling.
|
Cancer Res
|
2005
|
2.67
|
|
3
|
The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice.
|
Cancer Res
|
2007
|
1.81
|
|
4
|
Design and synthesis of tricyclic compounds with enone functionalities in rings A and C: a novel class of highly active inhibitors of nitric oxide production in mouse macrophages.
|
J Med Chem
|
2002
|
1.54
|
|
5
|
The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo.
|
Clin Cancer Res
|
2003
|
1.53
|
|
6
|
The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells.
|
Clin Cancer Res
|
2006
|
1.40
|
|
7
|
Synthetic triterpenoids enhance transforming growth factor beta/Smad signaling.
|
Cancer Res
|
2003
|
1.32
|
|
8
|
Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription.
|
PLoS One
|
2009
|
1.29
|
|
9
|
Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl Ester and the rexinoid LG100268.
|
Clin Cancer Res
|
2008
|
1.28
|
|
10
|
Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer.
|
Cancer Prev Res (Phila)
|
2010
|
1.19
|
|
11
|
Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis.
|
Free Radic Biol Med
|
2011
|
1.13
|
|
12
|
A novel acetylenic tricyclic bis-(cyano enone) potently induces phase 2 cytoprotective pathways and blocks liver carcinogenesis induced by aflatoxin.
|
Cancer Res
|
2008
|
1.06
|
|
13
|
Triterpenoids CDDO-methyl ester or CDDO-ethyl amide and rexinoids LG100268 or NRX194204 for prevention and treatment of lung cancer in mice.
|
Cancer Prev Res (Phila)
|
2009
|
1.03
|
|
14
|
The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer.
|
Clin Cancer Res
|
2006
|
1.03
|
|
15
|
The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis.
|
Mol Cancer Ther
|
2008
|
0.98
|
|
16
|
Design, synthesis, and anti-inflammatory activity both in vitro and in vivo of new betulinic acid analogues having an enone functionality in ring A.
|
Bioorg Med Chem Lett
|
2006
|
0.97
|
|
17
|
CDDO-methyl ester delays breast cancer development in BRCA1-mutated mice.
|
Cancer Prev Res (Phila)
|
2011
|
0.95
|
|
18
|
A new rexinoid, NRX194204, prevents carcinogenesis in both the lung and mammary gland.
|
Clin Cancer Res
|
2007
|
0.92
|
|
19
|
The synthetic triterpenoid CDDO-methyl ester delays estrogen receptor-negative mammary carcinogenesis in polyoma middle T mice.
|
Cancer Prev Res (Phila)
|
2012
|
0.92
|
|
20
|
Novel semisynthetic analogues of betulinic acid with diverse cytoprotective, antiproliferative, and proapoptotic activities.
|
Mol Cancer Ther
|
2007
|
0.90
|
|
21
|
Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268.
|
Clin Cancer Res
|
2002
|
0.89
|
|
22
|
The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer.
|
Cancer Res
|
2004
|
0.88
|
|
23
|
The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer.
|
Carcinogenesis
|
2012
|
0.85
|